Biogen Inc

BIIB

$326.73

+18.7% (1 year change)

Market Cap

$49.1 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$223.25 - $468.55

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

25.58x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $49.1 Billion
Enterprise Value $53.8 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +18.7%
52-Week High $468.55
52-Week Low $223.25
Beta 0.0
Outstanding Shares 149 Million
Avg 30 Day Volume 1.34 Million

Valuation

P/E Ratio 25.58
PEG -36.19
Earnings per Share $12.50
Price to Sales Ratio 3.89
Price to Book Ratio 4.6
Revenue to Enterprise Value 4.27
EBIT to Enterprise Value 15.38
Total Debt to Enterprise Value 0.14
Debt to Equity 0.68

Profitability

Revenue $12.6 Billion
Gross Profit $10.8 Billion
EBIT $3.5 Billion
Net Income $3.01 Billion
Profit Margin 23.89%
Quarterly Earnings Growth (YoY) -70.7%
Return on Equity 28.19%
Return on Assets 12.63%
Return on Invested Capital 16.91%

Biogen Inc

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

News

ARGA Investment Management, LP Buys Melco Resorts and Entertainment, II-VI Inc, Burford ...

ARGA Investment Management, LP Buys Melco Resorts and Entertainment, II-VI Inc, Burford ...

Related Stocks: MLCO , MCK , BABA , PKX , SKM , CMCSA , IIVI , BUR , LLY , RDY , MOS , BAC , BIIB , JD ,

GuruFocus GuruFocus, about 16 hours ago
Controversial Alzheimers drug highlights concerns about Health Canada approval process

Controversial Alzheimers drug highlights concerns about Health Canada approval process

Theres a new drug on the block to treat Alzheimers disease. On June 7, the United States Food and Drug Administration approved aducanumab (brand name Aduhelm), made by Biogen, the first new drug fo...

Philippine Canadian Inquirer Philippine Canadian Inquirer, 2 days ago
Global Adalimumab Market Will Reach $ 28,508.07 Million by 2027||Players-CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila

Global Adalimumab Market Will Reach $ 28,508.07 Million by 2027||Players-CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila

Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the...

OpenPR OpenPR, 3 days ago